Abstract: A device for influencing a patient's gait, comprising at least one foot lifter stimulation electrode for activating a foot lifter muscle, at least one sensor unit, at least one hip flexor stimulation electrode for activating a hip flexor muscle, and at least one control unit which is coupled to the sensor unit and the stimulation electrodes, processes sensor values from the sensor unit and, depending on the sensor values, activates at least one of the stimulation electrodes.

Abstract: The present invention provides a preparation comprising fibrinogen and a sulfated polysaccharide as a one component composition or as a kit of parts comprising fibrinogen and sulfated polysaccharide as separated components. The present invention further provides a fibrin clot like structure obtainable by a defined process, a hemostatic patch, a two-component syringe system and various uses of the described preparations, fibrin clot like structures and patches.

Abstract: The present invention relates to the use of fibroblast growth factor-binding protein (FGF-BP) polypeptides, and functional variants of these polypeptides, respectively, or of nucleic acids encoding these polypeptides or variants, or of functional variants of these nucleic acids, and/or of a cell which is expressing an FGF-BP polypeptide or functional variants thereof, for treating, diagnosing and/or preventing wound healing disturbances which are characterized by a reduced quantity of FGF-BP, in particular diabetes-associated wounds, and also to the use of at least one FGF-BP polypeptide as depicted in SEQ ID No. 1 and SEQ ID No. 3 and/or of at least one FGF-BP-encoding nucleic acid as depicted in SEQ ID No. 2 and SEQ ID No.

Abstract: The present invention relates to the use of Riluzole if needed with suitable adjuvants and additives for the production of a medicament for the treatment of diseases characterized by hyperproliferation of keratinocytes and/or T cells, in particular psoriasis and neurodermatitis as well as compositions comprising Riluzole and use thereof.

Abstract: The invention relates to the use of alpha 1-antichymotrypsin (ACT) polypeptides according to SEQ ID No. 1 to SEQ ID No. 4 and/or nucleic acids encoding them, or an antibody or a fragment thereof directed against the polypeptide, or of a cell which is expressing the polypeptide or a nucleic acid encoding it, for diagnosis, treatment and/or prevention of diabetes-associated and/or arterial wounds which heal poorly and for identifying pharmacologically active substances which exert an influence on the expression or function, particularly the activity of ACT.

Abstract: The invention relates to a use of alpha 1-antichymotrypsin (ACT) polypeptides, functional variants thereof and/or nucleic acids encoding them, or of a cell which is expressing an ACT polypeptide or a nucleic acid encoding it in combination with alpha-1-antitrypsin (AAT) polypeptides, functional variants thereof or nucleic acids encoding them, or of a cell which is expressing an AAT polypeptide, or a nucleic acid encoding it.

Abstract: The present invention relates to the use of fibroblast growth factor-binding protein (FGF-BP) polypeptides, and functional variants of these polypeptides, respectively, or of nucleic acids encoding these polypeptides or variants, or of functional variants of these nucleic acids, and/or of a cell which is expressing an FGF-BP polypeptide or functional variants thereof, for treating, diagnosing and/or preventing wound healing disturbances which are characterized by a reduced quantity of FGF-BP, in particular diabetes-associated wounds, and also to the use of at least one FGF-BP polypeptide as depicted in SEQ ID No. 1 and SEQ ID No. 3 and/or of at least one FGF-BP-encoding nucleic acid as depicted in SEQ ID No. 2 and SEQ ID No.

Abstract: The invention relates to the use of intermediate-conductance, calcium-activated potassium channels and/or the nucleic acids coding for the same, from humans or mice, for the diagnosis, prevention and/or treatment of illnesses associated with disturbed keratinocyte activity. The invention also relates to the use of the same for identifying pharmacologically active substances. The invention further relates to the use of modulators of intermediate-conductance, calcium-activated potassium channels for the diagnosis, prevention and/or treatment of illnesses associated with disturbed keratinocyte activity.

Abstract: Methods of promoting wound healing or treating a wound healing disorder in a patient and methods of preventing or treating a skin disorder in a patient are disclosed. As an active ingredient Eps 8 is disclosed.

Abstract: Method of using of polypeptides or nucleic acids encoding these for the diagnosis and/or prevention and/or treatment of diseases of skin cells and/or of wound healing and/or its pathological disorders, and their use for the identification of pharmacologically active substance.

Abstract: The invention relates to the use of alpha 1-antichymotrypsin (ACT) polypeptides according to SEQ ID No. 1 to SEQ ID No. 4 and/or nucleic acids encoding them, or an antibody or a fragment thereof directed against the polypeptide, or of a cell which is expressing the polypeptide or a nucleic acid encoding it, for diagnosis, treatment and/or prevention of diabetes-associated and/or arterial wounds which heal poorly and for identifying pharmacologically active substances which exert an influence on the expression or function, particularly the activity of ACT.

Abstract: The present invention relates to the use of an MRP8/MRP14 heterodimer, or of its individual components in combination, of at least one nucleic acid encoding the entire heterodimer or its individual components in combination, or of a cell which is expressing the entire heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds, and/or wound-healing disturbances having a reduced quantity of MRP8/MRP14 heterodimers, in particular diabetes-associated wounds, and to methods for identifying pharmacologically active substances which exert an influence on the function or expression of MRP8/MRP14 heterodimers.

Abstract: Polypeptides or nucleic acids encoding the polypeptides of a family of G-protein coupled receptors and their for use for prevention, diagnosis and/or treatment of disorders, for example skin disorders, and/or diagnosis and/or treatment in wound healing, and/or its pathological disorders and/or for identification of pharmacologically active substances.

Abstract: Method of using of polypeptides or nucleic acids encoding these for the diagnosis and/or prevention and/or treatment of diseases of skin cells and/or of wound healing and/or its pathological disorders, and their use for the identification of pharmacologically active substance.

Abstract: Method of using of polypeptides or nucleic acids encoding these, of the gene family NM23, for the analysis and/or diagnosis and/or prevention and/or treatment of disorders of skin and/or intestinal disorders and/or wound healing and/or disorders of wound healing and/or for the identification of pharmacologically active substances.

Abstract: Disclosed herein are cloning vectors which include: (a) a cloning site which permits the cloning of a nucleic acid in defined orientation; (b) at least one cleavage site adjacent to the cloning site, the cleavage site being rarely-occurring in nucleic acids; and (c) a long region which is located on the side of the cloning site opposite to the cleavage site (b), wherein the long region and the region between the cloning site and the cleavage site (b) contain neither the cloning site nor at least two frequently-occurring cleavage sites.